Eugenio Hardy is a researcher at the Center for Molecular Immunology (Havana, Cuba). His current research interests include functional immunotherapeutic nanostructures for oncological diseases. He received his PhD in Biological Sciences from the University of Havana in 1997. As Product Leader, he was instrumental in the development of the first industrial vaccine (Quimi-Hib®) against Haemophilus influenzae type b using a synthetic antigen, while working at the Center for Genetic Engineering and Biotechnology in Havana. He also contributed significantly to developing large-scale formulations and drug delivery systems related to vaccines (such as Heberbiovac HB®) and biologics (such as PEG-Heberon®). Dr. Hardy was a recipient of the Alexander von Humboldt Stiftung Award.